ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Effects of entecavir and tenofovir disoproxil fumarate on the incidence and severity of COVID-19 in patients with chronic hepatitis B

Liao, Xingmei; Fan, Yujie; Zhong, Chunxiu; Zhao, Siru; Guo, Liangxu; Tan, Wenjuan; Yin, Junhua; Fan, Rong*南方医科大学
BMC INFECTIOUS DISEASES2023-11-30DOI: 10.1186/s12879-023-08838-0
5阅读
引用收藏
分享

摘要

BackgroundWhether different anti-hepatitis B virus (HBV) drugs have different effects on COVID-19 is controversial. We aimed to evaluate the incidence of COVID-19 in chronic hepatitis B (CHB) patients receiving anti-HBV treatment, and to compare the impact of entecavir (ETV) and tenofovir disoproxil fumarate (TDF) on the severity of COVID-19.MethodsCHB outpatients were enrolled from December 2022 to February 2023. Questionnaires were used to collect whether subjects were currently or previously had COVID-19 within the past 2 months, and the information of symptoms, duration, and severity if infected.ResultsSix hundred thirty CHB patients were enrolled, 64.3% (405/630) patients were currently or previously had COVID-19. No COVID-19 patient required hospitalization, intensive care unit admission, oxygen support or died. Majority of patients reported mild (32.8% [133/405]) and moderate (48.1% [195/405]) symptoms. After propensity score matching, 400 matched patients were obtained (ETV: 238; TDF: 162), among which the incidences of COVID-19 were comparable between ETV and TDF-treated patients (60.1% [143/238] vs. 64.2% [104/162], p = 0.468). The proportion of patients complicated with any symptom caused by COVID-19 were also similar (ETV vs. TDF: 90.9% [130/143] vs. 91.3% [95/104], p = 1.000). In addition, the severity of overall symptom was comparable between ETV and TDF-treated patients, in terms of proportion of patients complicated with severe symptom (9.8% vs. 8.7%, p = 0.989), symptom duration (4.3 vs. 4.3 days, p = 0.927), and symptom severity score (4.1 vs. 4.0, p = 0.758). Subgroup analysis supported these results.ConclusionsDuring the current pandemic, the vast majority of CHB patients experienced non-severe COVID-19, and ETV and TDF did not affect COVID-19 severity differently.

学科与关键词

关键词
TenofovirEntecavirCOVID-19Chronic Hepatitis B
相关
加载中…
  • Real-life impact of tenofovir disoproxil fumarate and entecavir therapy on lipid profile, glucose, and uric acid in chronic hepatitis B patients
    Zhang, Qi; Liang, Jinlin; Yin, Junhua; Jiang, Yiyue; Yu, Ning; Liao, Xingmei; Zhao, Siru; Wu, Leyuan; Fan, Rong*Journal of Medical Virology, 2022, 94(11): 5465-5474.被引 2
  • Comparison of Efficacy and Safety of Tenofovir and Entecavir in Chronic Hepatitis B Virus Infection: A Systematic Review and Meta-Analysis
    Ke Weixia; Liu Li; Zhang Chi; Ye Xiaohua; Gao Yanhui; Zhou Shudong; Yang Yi*PLoS ONE, 2014, 9(6): e98865.
  • Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B
    Liu, Zhihong; Jin, Qinglong; Zhang, Yuexin; Gong, Guozhong; Wu, Guicheng; Yao, Lvfeng; Wen, Xiaofeng; Gao, Zhiliang; Huang, Yan; Yang, Daokun; Chen, Enqiang; Mao, Qing; Lin, Shide; Shang, Jia; Gong, Huanyu; Zhong, Lihua; Yin, Huafa; Wang, Fengmei; Hu, Peng; Xiao, Ling; Li, Chuan; Wu, Qiong; Sun, Chang'an; Niu, Junqi*; Hou, Jinlin*Alimentary Pharmacology and Therapeutics, 2021, 54(9): 1134-1149.被引 9
查看全部 →

发表信息

论文状态
公开发表
期刊
BMC INFECTIOUS DISEASES
发表日期
2023-11-30
卷期
第 23 卷, 第 1 期
页码
843
DOI
10.1186/s12879-023-08838-0
语言
ENGLISH
成果收录
SCIE
资助标注
Medical Science and Technology Research Foundation of Guangdong Province of China

作者

  • L

    Liao, Xingmei (第一作者)

    southern med univ

  • F

    Fan, Yujie

    southern med univ

查看全部 8 位作者收起作者
  • Z

    Zhong, Chunxiu

    southern med univ

  • Z

    Zhao, Siru

    southern med univ

  • G

    Guo, Liangxu

    southern med univ

  • T

    Tan, Wenjuan

    southern med univ

  • Y

    Yin, Junhua

    southern med univ

  • F

    Fan, Rong (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417